Delivery Order SPE2DR25D2014-SPE2DR26FZ88C
- Not listed
- The Defense Logistics Agency awarded a $1,323.98 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Lantus SoloStar 100 Unit/ml 3ml insulin pens. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by December 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens with a ceiling value of $4,398.30. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. Performance will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a $4,038.26 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on June 13, 2025, with an ultimate completion date of June 16, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,505.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a $1,317.48 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 24, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,095.17 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on December 18, 2025, with completion scheduled for December 19, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $1,222.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. The award was made on December 1, 2025, with an ultimate completion date of December 2, 2025, and represents a non-competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,473.93 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on August 4, 2025, with completion targeted for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $2,547.42 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens, with a completion date of November 5, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a routine pharmaceutical procurement for military healthcare supply. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $1,534.20 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on September 22, 2025, with a completion date of September 23, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ88CDelivery Order
The Defense Logistics Agency awarded a $4,967.84 delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania, with an ultimate completion date of December 5, 2025. This award involved no set-aside designation, indicating competitive selection among qualified vendors. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical supplier for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical and medical supply requirements, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. This delivery order for insulin reflects the company's ongoing role in supporting military and federal healthcare programs' pharmaceutical needs through the DLA's comprehensive medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 12/3/25 |